DOCSLIB.ORG

Ketoconazole and Posaconazole Selectively Target HK2-Expressing Glioblastoma Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ketoconazole and Posaconazole Selectively Target HK2-Expressing Glioblastoma Cells Published OnlineFirst October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1854 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Sameer Agnihotri1, Sheila Mansouri2, Kelly Burrell2, Mira Li2, Mamatjan Yasin, MD2, Jeff Liu2,3, Romina Nejad2, Sushil Kumar2, Shahrzad Jalali2, Sanjay K. Singh2, Alenoush Vartanian2,4, Eric Xueyu Chen5, Shirin Karimi2, Olivia Singh2, Severa Bunda2, Alireza Mansouri7, Kenneth D. Aldape2,6, and Gelareh Zadeh2,7 Abstract Purpose: Hexokinase II (HK2) protein expression is eleva- in vivo. Treatment of mice bearing GBM with ketoconazole ted in glioblastoma (GBM), and we have shown that HK2 and posaconazole increased their survival, reduced tumor could serve as an effective therapeutic target for GBM. Here, we cell proliferation, and decreased tumor metabolism. In interrogated compounds that target HK2 effectively and addition, treatment with azoles resulted in increased pro- restrict tumor growth in cell lines, patient-derived glioma stem portion of apoptotic cells. cells (GSCs), and mouse models of GBM. Conclusions: Overall, we provide evidence that azoles exert Experimental Design: We performed a screen using a set of their effect by targeting genes and pathways regulated by HK2. 15 drugs that were predicted to inhibit the HK2-associated These findings shed light on the action of azoles in GBM. gene signature. We next determined the EC50 of the com- Combined with existing literature and preclinical results, these pounds by treating glioma cell lines and GSCs. Selected data support the value of repurposing azoles in GBM clinical compounds showing significant impact in vitro were used to trials. treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic Significance: The results of this study provide a mechanistic activity in glioma cells was also assessed in vitro. understanding of the action of azoles in patients with GBM, Results: This screen identified the azole class of antifun- together with preclinical results that lend further support gals as inhibitors of tumor metabolism. Among the com- to existing literature on the value of investigating azoles pounds tested, ketoconazole and posaconazole displayed as repurposed drugs in clinical trials for patients with GBM. the greatest inhibitory effect on GBM both in vitro and Clin Cancer Res; 1–12. Ó2018 AACR. Introduction tions. This process is referred to as the "Warburg effect" or aerobic glycolysis (1). This metabolic remodeling seen in cancer cells Cancer cells exhibit a key distinguishing feature compared with results in alteration of synthesis and utilization of metabolites. It normal cells in how they generate ATP. Cancer cells generate more was originally thought that solid tumors benefit from the Warburg than 50% of their ATP from glycolysis rather than oxidative effect through enhanced glycolytic flux and faster ATP production phosphorylation (OXPHOS), even under high oxygen condi- per glucose molecule, ensuring sufficient supply of ATP for rapidly proliferating tumor cells, in particular under hypoxic conditions 1Department of Neurological Surgery, Children's Hospital of Pittsburgh, Univer- (2). However, metabolic reprogramming is utilized even under 2 sity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. MacFeeters- sufficient supply of oxygen and nutrients, suggesting that there are Hamilton Center for Neuro-Oncology Research, Princess Margaret Cancer other advantages of metabolic reprogramming for cancer cell Center, Toronto, Ontario, Canada. 3Donnelly Centre for Cellular and Biomolec- ular Research, University of Toronto, Toronto, Ontario, Canada. 4Geisinger Holy survival (1). Spirit Healthcare Network, Harrisburg, PA. 5Division of Medical Oncology and Glioblastoma (GBM) is the most common primary brain Haematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, tumor in adults, displaying high therapeutic resistance and Ontario, Canada. 6Laboratory of Pathology, NCI, Bethesda, Massachusetts. poor median survival of 12–18 months (3). To date, there has 7 Toronto Western Hospital, Toronto, Ontario, Canada. been no advance in targeted therapies for GBMs. Our group and Note: Supplementary data for this article are available at Clinical Cancer others have shown that metabolic reprogramming plays an Research Online (http://clincancerres.aacrjournals.org/). important role in tumor progression in GBM. We have shown S. Agnihotri and S. Mansouri contributed equally to this article. that the glycolytic enzyme, hexokinase II (HK2), plays an fl Corresponding Authors: Gelareh Zadeh, MacFeeters-Hamilton Center for Neuro- important role in glucose ux into glycolysis or the pentose Oncology Research, Princess, Margaret Cancer Center, Toronto, Ontario, Canada, phosphate pathway (PPP) and its transcription is tightly reg- M5G 1L7. Phone: 416-634-8728; Fax: 416-603-5298; E-mail: [email protected]; ulated in part by HIF1a,glucose,cAMP,insulin,glucagon,and and Sameer Agnihotri, Children's Hospital of Pittsburgh, University of Pittsburgh p53 (4). Specifically, we have also shown that downregulation School of Medicine, Rangos Research Center, 7th Floor, Bay 15, 530, 45th Street, of HK2 inhibits aerobic glycolysis, while promoting oxidative Pittsburgh, PA 15201. Fax: 412-692-5921; E-mail: [email protected] phosphorylation (OXPHOS), as demonstrated by increased O2 doi: 10.1158/1078-0432.CCR-18-1854 consumption, decreased extracellular lactate, and increased Ó2018 American Association for Cancer Research. expression of genes involved in OXPHOS (5). Furthermore, www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1854 Agnihotri et al. Given the limited progress in the field of therapeutics for GBM, Translational Relevance there is a pressing need to expand the available treatment options Through a systematic drug screening approach, we identi- through translation of preclinical discoveries to clinical trials. One fied ketoconazole and posaconazole as inhibitors of hexoki- possible means to expedite initiation of GBM clinical trials is nase II (HK2). We have demonstrated that both drugs decrease through drug repurposing, by examining previously established tumor growth likely through blocking HK2 and affecting drugs with a known track record of safety in humans. We hypoth- tumor metabolism. Prior studies suggested azoles as effective esized that identifying gene networks associated with HK2 and therapeutic compounds for gliomas and here, we have estab- their selective targeting can reveal novel therapeutic options for lished the mechanism by which they influence glioblastoma GBM by inhibiting glycolysis, promoting OXPHOS, and reduc- (GBM) metabolism, oncogenic pathways regulated by HK2, ing proliferation. Using a systems biology approach, we estab- and growth and progression of GBM. Two azoles, ketocona- lished the gene signature and pathways that are affected upon zole and posaconazole, displayed selective antitumoral prop- downregulation of HK2 to identify novel therapeutic vulner- erties in GBM cells and led to significant in vivo survival abilities. Using a drug screen targeting potential HK2-regulated benefits, including reduced proliferation and increased apo- gene expression networks, we identified the azole class of ptosis in 3 independent mouse models. In addition, we antifungals as inhibitors. We examined the effect of azoles established that azoles cross the blood–brain barrier (BBB) in vitro and in vivo on GBM metabolism and their potency as and exert their antimetabolic action through inhibition of inhibitors of tumor growth. HK2 activity. We show that decrease in HK2 results in a distinct shift in gene expression and oncogenic pathway regulation. Materials and Methods Overall, these results lend further mechanistic support to Cell culture azoles being repurposed into practice through clinical trials Fetal normal human astrocytes (NHAs) immortalized with for patients with GBM. hTERT were purchased from ABM. U87, T98G, U251, and U118 cell lines were purchased from ATCC. Cells were grown in DMEM and 10% FBS. Normal neural stem cells (NSCs) were purchased from Thermo Fisher Scientific. Glioma stem cells we have shown that decreased HK2 expression results in sen- (GSC;GSC8-18,GSC7-2,GBM8,andGSC30)werederived sitization of tumor cells to radiation and chemotherapy, con- from human operative samples as described previously and comitant with increased survival of GBM mouse models. We cultured in GSC media (12). All cells were subjected to short have proven that the function of HK2 is independent of its tandem repeat (STR) profiling and confirmed Mycoplasma isoform HK1 (5). Collectively, this evidence supports that HK2 negative by PCR testing. is a key driver of metabolic regulation in GBMs as it regulates tumor growth and proliferation and is in part responsible for resistance to chemoradiation. Viability assays and EC50 analysis Currently, no direct inhibitors of HK2 have been tested in Cell viability assays were performed using the CellTiter-Glo human patients with GBM due to the inability of the drugs to Luminescent Cell Viability Assay (Promega) as per manufacturer's cross the blood–brain barrier (BBB) or concern for their toxicity protocol. Raw luminescent values were inputted into PRISM 7.0. in patients. For example, 3-bromopyruvate
Load more

Recommended publications
  • Progressive Increase in Mtdna 3243A>G Heteroplasmy Causes Abrupt
    Progressive increase in mtDNA 3243A>G PNAS PLUS heteroplasmy causes abrupt transcriptional reprogramming Martin Picarda, Jiangwen Zhangb, Saege Hancockc, Olga Derbenevaa, Ryan Golhard, Pawel Golike, Sean O’Hearnf, Shawn Levyg, Prasanth Potluria, Maria Lvovaa, Antonio Davilaa, Chun Shi Lina, Juan Carlos Perinh, Eric F. Rappaporth, Hakon Hakonarsonc, Ian A. Trouncei, Vincent Procaccioj, and Douglas C. Wallacea,1 aCenter for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; bSchool of Biological Sciences, The University of Hong Kong, Hong Kong, People’s Republic of China; cTrovagene, San Diego, CA 92130; dCenter for Applied Genomics, Division of Genetics, Department of Pediatrics, and hNucleic Acid/Protein Research Core Facility, Children’s Hospital of Philadelphia, Philadelphia, PA 19104; eInstitute of Genetics and Biotechnology, Warsaw University, 00-927, Warsaw, Poland; fMorton Mower Central Research Laboratory, Sinai Hospital of Baltimore, Baltimore, MD 21215; gGenomics Sevices Laboratory, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806; iCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia; and jDepartment of Biochemistry and Genetics, National Center for Neurodegenerative and Mitochondrial Diseases, Centre Hospitalier Universitaire d’Angers, 49933 Angers, France Contributed by Douglas C. Wallace, August 1, 2014 (sent for review May
    [Show full text]
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
    [Show full text]
  • TRP Mediation
    molecules Review Remedia Sternutatoria over the Centuries: TRP Mediation Lujain Aloum 1 , Eman Alefishat 1,2,3 , Janah Shaya 4 and Georg A. Petroianu 1,* 1 Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates; [email protected] (L.A.); Eman.alefi[email protected] (E.A.) 2 Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates 3 Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman 11941, Jordan 4 Pre-Medicine Bridge Program, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates; [email protected] * Correspondence: [email protected]; Tel.: +971-50-413-4525 Abstract: Sneezing (sternutatio) is a poorly understood polysynaptic physiologic reflex phenomenon. Sneezing has exerted a strange fascination on humans throughout history, and induced sneezing was widely used by physicians for therapeutic purposes, on the assumption that sneezing eliminates noxious factors from the body, mainly from the head. The present contribution examines the various mixtures used for inducing sneezes (remedia sternutatoria) over the centuries. The majority of the constituents of the sneeze-inducing remedies are modulators of transient receptor potential (TRP) channels. The TRP channel superfamily consists of large heterogeneous groups of channels that play numerous physiological roles such as thermosensation, chemosensation, osmosensation and mechanosensation. Sneezing is associated with the activation of the wasabi receptor, (TRPA1), typical ligand is allyl isothiocyanate and the hot chili pepper receptor, (TRPV1), typical agonist is capsaicin, in the vagal sensory nerve terminals, activated by noxious stimulants.
    [Show full text]
  • Clotrimazole (Topical) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Clotrimazole (Topical) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US 3 Day Vaginal [OTC]; Alevazol [OTC]; Antifungal (Clotrimazole) [OTC]; Antifungal Clotrimazole [OTC]; Clotrimazole 3 Day [OTC]; Clotrimazole Anti-Fungal [OTC]; Clotrimazole GRx [OTC] [DSC]; Desenex [OTC]; Gyne-Lotrimin 3 [OTC]; Gyne- Lotrimin [OTC]; Lotrimin AF For Her [OTC] [DSC]; Pro-Ex Antifungal [OTC]; Shopko Athletes Foot [OTC] [DSC] What is this drug used for? It is used to treat fungal infections of the skin. This drug is used to treat vaginal yeast infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? All products: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. All skin products: If you have nail or scalp infections. This drug will not work to treat nail or scalp infections. Clotrimazole (Topical) 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
    [Show full text]
  • Pharmacological Inhibition of Tumor Anabolism and Host Catabolism As A
    www.nature.com/scientificreports OPEN Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy Alejandro Schcolnik‑Cabrera1,2, Alma Chavez‑Blanco1, Guadalupe Dominguez‑Gomez1, Mandy Juarez1, Ariana Vargas‑Castillo3, Rafael Isaac Ponce‑Toledo4, Donna Lai5, Sheng Hua5, Armando R. Tovar3, Nimbe Torres3, Delia Perez‑Montiel6, Jose Diaz‑Chavez1 & Alfonso Duenas‑Gonzalez1,7* The malignant energetic demands are satisfed through glycolysis, glutaminolysis and de novo synthesis of fatty acids, while the host curses with a state of catabolism and systemic infammation. The concurrent inhibition of both, tumor anabolism and host catabolism, and their efect upon tumor growth and whole animal metabolism, have not been evaluated. We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin). Treatment reduced cellular viability, clonogenic capacity and cell cycle progression. These efects were associated with decreased glycolysis and oxidative phosphorylation, leading to a quiescent energetic phenotype, and with an aberrant transcriptomic landscape showing dysregulation in multiple metabolic pathways. The in vivo evaluation revealed a signifcant tumor volume inhibition, without damage to normal tissues. The six‑drug combination preserved lean tissue and decreased fat loss, while the energy expenditure got decreased. Finally, a reduction in gene expression associated with thermogenesis was observed. Our fndings demonstrate that the simultaneous use of this six‑drug combination has anticancer efects by inducing a quiescent energetic phenotype of cultured cancer cells. Besides, the treatment is well‑ tolerated in mice and reduces whole animal energetic expenditure and fat loss.
    [Show full text]
  • Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc
    Poster Title Here Mitochondrial Deficiency in Primary Muscle Cells from Mdx Mice Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc. Cambridge, MA 02138 Abstract Results Results Duchenne muscular dystrophy (DMD) is a recessive, fatal X-linked disease that is characterized M ito c h o n d ria l c o n trib u te d A T P is re d u c e d Mdx myoblasts have decreased expression by progressive skeletal muscle wasting due to a loss of function in dystrophin, a protein that is of OXPHOS complexes part of a complex that bridges the cytoskeleton and extracellular matrix. The mdx mouse, an in m d x m y o b la s ts a n d m y o tu b e s T animal model for DMD, has a point mutation in the dystrophin gene that results in a loss of 1 .5 2.0 W l function. This study uses primary muscle satellite cell derived myoblasts and myotubes to W T a WT m determine differences in mitochondrial biology between the mdx mice and wild type (WT) control s M D X o 1.5 a r MDX mice. Compared to cells isolated from WT mice, mdx cells have reductions in mitochondrial 1 .0 **** f B bioenergetics. Moreover, mdx cells have reduced levels of mitochondria which may partially *** e T g 1.0 explain the reduction in bioenergetics. Interestingly, the mitochondrial phenotype is apparent **** ** n * * W a * * * before dystrophin protein is increased during myogenesis. * * * 0 .5 h 0.5 * d l C o d l F 0.0 o 1 3 2 6 1 a 1 a b B 0 .0 F t v Materials and Analysis a 5 P X D C H H y 5 l l F X T N R O D a M in a M in D C s s P n n U A c c O S C C a 0 a 0 S y y T B 0 B 0 D WT and mdx myoblast isolation and culture: Quadricep and gastrocnemius muscles from a C 1 m 1 m Q A o o N single mouse were pooled and subjected to a mechanical/collagenase digestion.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Self-Nano-Emulsifying Drug-Delivery Systems: from the Development to the Current Applications and Challenges in Oral Drug Delivery
    pharmaceutics Review Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery Aristote B. Buya 1,2 , Ana Beloqui 1, Patrick B. Memvanga 2 and Véronique Préat 1,* 1 Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université Catholique de Louvain, Avenue Mounier 73, B1.73.12, 1200 Brussels, Belgium; [email protected] (A.B.B.); [email protected] (A.B.) 2 Pharmaceutics and Phytopharmaceutical Drug Development Research Group, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI BP 212, Democratic Republic of the Congo; [email protected] * Correspondence: [email protected]; Tel.: +32-27647309 Received: 3 November 2020; Accepted: 5 December 2020; Published: 9 December 2020 Abstract: Approximately one third of newly discovered drug molecules show insufficient water solubility and therefore low oral bio-availability. Self-nano-emulsifying drug-delivery systems (SNEDDSs) are one of the emerging strategies developed to tackle the issues associated with their oral delivery. SNEDDSs are composed of an oil phase, surfactant, and cosurfactant or cosolvent. SNEDDSs characteristics, their ability to dissolve a drug, and in vivo considerations are determinant factors in the choice of SNEDDSs excipients. A SNEDDS formulation can be optimized through phase diagram approach or statistical design of experiments. The characterization of SNEDDSs includes multiple orthogonal methods required to fully control SNEDDS manufacture, stability, and biological fate. Encapsulating a drug in SNEDDSs can lead to increased solubilization, stability in the gastro-intestinal tract, and absorption, resulting in enhanced bio-availability. The transformation of liquid SNEDDSs into solid dosage forms has been shown to increase the stability and patient compliance.
    [Show full text]
  • Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: an Update
    International Journal of Molecular Sciences Review Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update Philippe Icard 1,2,3,*, Antoine Coquerel 1,4, Zherui Wu 5 , Joseph Gligorov 6, David Fuks 7, Ludovic Fournel 3,8, Hubert Lincet 9,10 and Luca Simula 11 1 Medical School, Université Caen Normandie, CHU de Caen, 14000 Caen, France; [email protected] 2 UNICAEN, INSERM U1086 Interdisciplinary Research Unit for Cancer Prevention and Treatment, Normandie Université, 14000 Caen, France 3 Service de Chirurgie Thoracique, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, APHP, Paris-Descartes University, 75014 Paris, France; [email protected] 4 INSERM U1075, COMETE Mobilités: Attention, Orientation, Chronobiologie, Université Caen, 14000 Caen, France 5 School of Medicine, Shenzhen University, Shenzhen 518000, China; [email protected] 6 Oncology Department, Tenon Hospital, Pierre et Marie Curie University, 75020 Paris, France; [email protected] 7 Service de Chirurgie Digestive et Hépato-Biliaire, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, APHP, Paris-Descartes University, 75014 Paris, France; [email protected] 8 Descartes Faculty of Medicine, University of Paris, Paris Center, 75006 Paris, France 9 INSERM U1052, CNRS UMR5286, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; [email protected] 10 ISPB, Faculté de Pharmacie, Université Lyon 1, 69373 Lyon, France 11 Department of Infection, Immunity and Inflammation, Institut Cochin, INSERM U1016, CNRS UMR8104, Citation: Icard, P.; Coquerel, A.; Wu, University of Paris, 75014 Paris, France; [email protected] Z.; Gligorov, J.; Fuks, D.; Fournel, L.; * Correspondence: [email protected] Lincet, H.; Simula, L.
    [Show full text]
  • PIM2-Mediated Phosphorylation of Hexokinase 2 Is Critical for Tumor Growth and Paclitaxel Resistance in Breast Cancer
    Oncogene (2018) 37:5997–6009 https://doi.org/10.1038/s41388-018-0386-x ARTICLE PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer 1 1 1 1 1 2 2 3 Tingting Yang ● Chune Ren ● Pengyun Qiao ● Xue Han ● Li Wang ● Shijun Lv ● Yonghong Sun ● Zhijun Liu ● 3 1 Yu Du ● Zhenhai Yu Received: 3 December 2017 / Revised: 30 May 2018 / Accepted: 31 May 2018 / Published online: 9 July 2018 © The Author(s) 2018. This article is published with open access Abstract Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and 1234567890();,: 1234567890();,: enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer. Introduction ATP molecules.
    [Show full text]
  • Snapshot: Mammalian TRP Channels David E
    SnapShot: Mammalian TRP Channels David E. Clapham HHMI, Children’s Hospital, Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA TRP Activators Inhibitors Putative Interacting Proteins Proposed Functions Activation potentiated by PLC pathways Gd, La TRPC4, TRPC5, calmodulin, TRPC3, Homodimer is a purported stretch-sensitive ion channel; form C1 TRPP1, IP3Rs, caveolin-1, PMCA heteromeric ion channels with TRPC4 or TRPC5 in neurons -/- Pheromone receptor mechanism? Calmodulin, IP3R3, Enkurin, TRPC6 TRPC2 mice respond abnormally to urine-based olfactory C2 cues; pheromone sensing 2+ Diacylglycerol, [Ca ]I, activation potentiated BTP2, flufenamate, Gd, La TRPC1, calmodulin, PLCβ, PLCγ, IP3R, Potential role in vasoregulation and airway regulation C3 by PLC pathways RyR, SERCA, caveolin-1, αSNAP, NCX1 La (100 µM), calmidazolium, activation [Ca2+] , 2-APB, niflumic acid, TRPC1, TRPC5, calmodulin, PLCβ, TRPC4-/- mice have abnormalities in endothelial-based vessel C4 i potentiated by PLC pathways DIDS, La (mM) NHERF1, IP3R permeability La (100 µM), activation potentiated by PLC 2-APB, flufenamate, La (mM) TRPC1, TRPC4, calmodulin, PLCβ, No phenotype yet reported in TRPC5-/- mice; potentially C5 pathways, nitric oxide NHERF1/2, ZO-1, IP3R regulates growth cones and neurite extension 2+ Diacylglycerol, [Ca ]I, 20-HETE, activation 2-APB, amiloride, Cd, La, Gd Calmodulin, TRPC3, TRPC7, FKBP12 Missense mutation in human focal segmental glomerulo- C6 potentiated by PLC pathways sclerosis (FSGS); abnormal vasoregulation in TRPC6-/-
    [Show full text]
  • Drugs Interfering with the Metabolism of Tacrolimus (FK506)
    BLOOD SCIENCES DEPARTMENT OF CLINICAL BIOCHEMISTRY Title of Document: Drugs Interfering with the metabolism of tacrolimus (FK506) Q Pulse Reference No: BS/CB/DCB/TOX/4 Version NO: 6 Authoriser: P Beresford Page 1 of 3 Drugs Interfering with the Metabolism of Tacrolimus (FK506) Introduction Tacrolimus (FK506) is an immunosuppressant drug. The purpose of this protocol is to highlight drug interactions in the metabolism of tacrolimus (FK506) Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of medicinal products or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. It is therefore recommended to monitor tacrolimus blood levels whenever substances which have the potential to alter CYP3A metabolism are used concomitantly and to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure Inhibitors of metabolism Clinically the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole and voriconazole, the macrolide antibiotic erythromycin or HIV protease inhibitors (e.g. ritonavir). Concomitant use of these substances may require decreased tacrolimus doses in nearly all patients. Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, danazol, ethinylestradiol, omeprazole and nefazodone. In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen, troleandomycin. Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.
    [Show full text]